Impact of activated vitamin D and race on survival among hemodialysis patients

Myles Wolf, Joseph Betancourt, Yuchiao Chang, Anand Shah, Ming Teng, Hector Tamez, Orlando Gutierrez, Carlos A. Camargo, Michal L. Melamed, Keith Norris, Meir J. Stampfer, Neil R. Powe, Ravi Thadhani

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Contrary to most examples of disparities in health outcomes, black patients have improved survival compared with white patients after initiating hemodialysis. Understanding potential explanations for this observation may have important clinical implications for minorities in general. This study tested the hypothesis that greater use of activated vitamin D therapy accounts for the survival advantage observed in black and Hispanic patients on hemodialysis. In a prospective cohort of non-Hispanic white (n = 5110), Hispanic white (n = 979), and black (n = 3214) incident hemodialysis patients, higher parathyroid hormone levels at baseline were the primary determinant of prescribing activated vitamin D therapy. Median parathyroid hormone was highest among black patients, who were most likely to receive activated vitamin D and at the highest dosage. One-year mortality was lower in black and Hispanic patients compared with white patients (16 and 16 versus 23%; P < 0.01), but there was significant interaction between race and ethnicity, activated vitamin D therapy, and survival. In multivariable analyses of patients treated with activated vitamin D, black patients had 16% lower mortality compared with white patients, but the difference was lost when adjusted for vitamin D dosage. In contrast, untreated black patients had 35% higher mortality compared with untreated white patients, an association that persisted in several sensitivity analyses. In conclusion, therapy with activated vitamin D may be one potential explanation for the racial differences in survival among hemodialysis patients. Further studies should determine whether treatment differences based on biologic differences contribute to disparities in other conditions.

Original languageEnglish (US)
Pages (from-to)1379-1388
Number of pages10
JournalJournal of the American Society of Nephrology
Volume19
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Vitamin D
Renal Dialysis
Survival
Hispanic Americans
Parathyroid Hormone
Mortality
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Wolf, M., Betancourt, J., Chang, Y., Shah, A., Teng, M., Tamez, H., ... Thadhani, R. (2008). Impact of activated vitamin D and race on survival among hemodialysis patients. Journal of the American Society of Nephrology, 19(7), 1379-1388. https://doi.org/10.1681/ASN.2007091002

Impact of activated vitamin D and race on survival among hemodialysis patients. / Wolf, Myles; Betancourt, Joseph; Chang, Yuchiao; Shah, Anand; Teng, Ming; Tamez, Hector; Gutierrez, Orlando; Camargo, Carlos A.; Melamed, Michal L.; Norris, Keith; Stampfer, Meir J.; Powe, Neil R.; Thadhani, Ravi.

In: Journal of the American Society of Nephrology, Vol. 19, No. 7, 07.2008, p. 1379-1388.

Research output: Contribution to journalArticle

Wolf, M, Betancourt, J, Chang, Y, Shah, A, Teng, M, Tamez, H, Gutierrez, O, Camargo, CA, Melamed, ML, Norris, K, Stampfer, MJ, Powe, NR & Thadhani, R 2008, 'Impact of activated vitamin D and race on survival among hemodialysis patients', Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1379-1388. https://doi.org/10.1681/ASN.2007091002
Wolf, Myles ; Betancourt, Joseph ; Chang, Yuchiao ; Shah, Anand ; Teng, Ming ; Tamez, Hector ; Gutierrez, Orlando ; Camargo, Carlos A. ; Melamed, Michal L. ; Norris, Keith ; Stampfer, Meir J. ; Powe, Neil R. ; Thadhani, Ravi. / Impact of activated vitamin D and race on survival among hemodialysis patients. In: Journal of the American Society of Nephrology. 2008 ; Vol. 19, No. 7. pp. 1379-1388.
@article{7c09559d596747b7b5606121ee7dfaa7,
title = "Impact of activated vitamin D and race on survival among hemodialysis patients",
abstract = "Contrary to most examples of disparities in health outcomes, black patients have improved survival compared with white patients after initiating hemodialysis. Understanding potential explanations for this observation may have important clinical implications for minorities in general. This study tested the hypothesis that greater use of activated vitamin D therapy accounts for the survival advantage observed in black and Hispanic patients on hemodialysis. In a prospective cohort of non-Hispanic white (n = 5110), Hispanic white (n = 979), and black (n = 3214) incident hemodialysis patients, higher parathyroid hormone levels at baseline were the primary determinant of prescribing activated vitamin D therapy. Median parathyroid hormone was highest among black patients, who were most likely to receive activated vitamin D and at the highest dosage. One-year mortality was lower in black and Hispanic patients compared with white patients (16 and 16 versus 23{\%}; P < 0.01), but there was significant interaction between race and ethnicity, activated vitamin D therapy, and survival. In multivariable analyses of patients treated with activated vitamin D, black patients had 16{\%} lower mortality compared with white patients, but the difference was lost when adjusted for vitamin D dosage. In contrast, untreated black patients had 35{\%} higher mortality compared with untreated white patients, an association that persisted in several sensitivity analyses. In conclusion, therapy with activated vitamin D may be one potential explanation for the racial differences in survival among hemodialysis patients. Further studies should determine whether treatment differences based on biologic differences contribute to disparities in other conditions.",
author = "Myles Wolf and Joseph Betancourt and Yuchiao Chang and Anand Shah and Ming Teng and Hector Tamez and Orlando Gutierrez and Camargo, {Carlos A.} and Melamed, {Michal L.} and Keith Norris and Stampfer, {Meir J.} and Powe, {Neil R.} and Ravi Thadhani",
year = "2008",
month = "7",
doi = "10.1681/ASN.2007091002",
language = "English (US)",
volume = "19",
pages = "1379--1388",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Impact of activated vitamin D and race on survival among hemodialysis patients

AU - Wolf, Myles

AU - Betancourt, Joseph

AU - Chang, Yuchiao

AU - Shah, Anand

AU - Teng, Ming

AU - Tamez, Hector

AU - Gutierrez, Orlando

AU - Camargo, Carlos A.

AU - Melamed, Michal L.

AU - Norris, Keith

AU - Stampfer, Meir J.

AU - Powe, Neil R.

AU - Thadhani, Ravi

PY - 2008/7

Y1 - 2008/7

N2 - Contrary to most examples of disparities in health outcomes, black patients have improved survival compared with white patients after initiating hemodialysis. Understanding potential explanations for this observation may have important clinical implications for minorities in general. This study tested the hypothesis that greater use of activated vitamin D therapy accounts for the survival advantage observed in black and Hispanic patients on hemodialysis. In a prospective cohort of non-Hispanic white (n = 5110), Hispanic white (n = 979), and black (n = 3214) incident hemodialysis patients, higher parathyroid hormone levels at baseline were the primary determinant of prescribing activated vitamin D therapy. Median parathyroid hormone was highest among black patients, who were most likely to receive activated vitamin D and at the highest dosage. One-year mortality was lower in black and Hispanic patients compared with white patients (16 and 16 versus 23%; P < 0.01), but there was significant interaction between race and ethnicity, activated vitamin D therapy, and survival. In multivariable analyses of patients treated with activated vitamin D, black patients had 16% lower mortality compared with white patients, but the difference was lost when adjusted for vitamin D dosage. In contrast, untreated black patients had 35% higher mortality compared with untreated white patients, an association that persisted in several sensitivity analyses. In conclusion, therapy with activated vitamin D may be one potential explanation for the racial differences in survival among hemodialysis patients. Further studies should determine whether treatment differences based on biologic differences contribute to disparities in other conditions.

AB - Contrary to most examples of disparities in health outcomes, black patients have improved survival compared with white patients after initiating hemodialysis. Understanding potential explanations for this observation may have important clinical implications for minorities in general. This study tested the hypothesis that greater use of activated vitamin D therapy accounts for the survival advantage observed in black and Hispanic patients on hemodialysis. In a prospective cohort of non-Hispanic white (n = 5110), Hispanic white (n = 979), and black (n = 3214) incident hemodialysis patients, higher parathyroid hormone levels at baseline were the primary determinant of prescribing activated vitamin D therapy. Median parathyroid hormone was highest among black patients, who were most likely to receive activated vitamin D and at the highest dosage. One-year mortality was lower in black and Hispanic patients compared with white patients (16 and 16 versus 23%; P < 0.01), but there was significant interaction between race and ethnicity, activated vitamin D therapy, and survival. In multivariable analyses of patients treated with activated vitamin D, black patients had 16% lower mortality compared with white patients, but the difference was lost when adjusted for vitamin D dosage. In contrast, untreated black patients had 35% higher mortality compared with untreated white patients, an association that persisted in several sensitivity analyses. In conclusion, therapy with activated vitamin D may be one potential explanation for the racial differences in survival among hemodialysis patients. Further studies should determine whether treatment differences based on biologic differences contribute to disparities in other conditions.

UR - http://www.scopus.com/inward/record.url?scp=48149102507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149102507&partnerID=8YFLogxK

U2 - 10.1681/ASN.2007091002

DO - 10.1681/ASN.2007091002

M3 - Article

VL - 19

SP - 1379

EP - 1388

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -